MEDINET is collecting and building clinical evidences, and constructing a data base in order to build Immuno-Cell Therapy as evidence based medicine (EBM) so that an improved understanding and recognition of the immuno-cell therapy can be accomplished, and the best immuno-cell therapy, which is clearer and easy to understand, can be provided to patients.

(1) Collection and Building of Evidences through Clinical Studies We are conducting to explore more effective administration methods and combination methods, and in collecting and building evidence for development of new immuno-cell therapy, through coordination and data management in collaborative clinical studies with contracted medical organizations of MEDINET, and external medical organizations (university hospitals, regional core hospitals).

(2) Collection and Building of Clinical Data from Literature Survey MEDINET is collecting clinical data on immuno-cell therapies from publications of medical congresses and medical literature, as well as constructing and updating a database. MEDINET is also striving to build a system by which the most appropriate information required for each patient can be obtained from this database and can be provided to medical institutions.

In addition to the above, MEDINET is developing evaluation methods from the patient’s point of view such as QOL and symptom control , and is striving to elucidate the usefulness of the immuno-cell therapy more clearly.

MEDINET is also conducting the verification of the efficacy and safety of the immuno-cell therapy by collecting and building clinical evidence from various angles and performing data analysis.

[Themes of Clinical Study which MEDINET joins] * Usefulness of combination therapy of chemotherapy and DC (dendritic cell) Vaccine + αβT-Cell Therapy therapy for unresectable pancreatic cancer * Usefulness ofγδT cell administration for multiple myeloma. * Usefulness ofγδT cell administration for non-small cell lung cancer. * Combination of chemotherapy and αβT-Cell Therapy for pancreatic cancer after curative resection. * DC (dendritic cell) Vaccine therapy for recurrent hepatic cancer after RFA.